PATENT ABSTRACTS 117

separating xanthan from the culture medium, is provided along with specific DNA sequences and Xanthomonas campestris strains showing increased xanthan gum production.

protective 41kD antigen bend from P. fal- ciparum protects Aotus monkeys completely from a P. falciparum infection in model experi- ments.

5194387

P R O C E S S F O R T H E I N C O R P O R A T I O N O F DNA

M O L E C U L E S I N T O M I C R O O R G A N I S M S W I T H

M E T H Y L - S P E C I F I C R E S T R I C T I O N S Y S T E M S

Douglas J MacNeit assigned to Merck & Co Inc

There is disclosed a process for the incorpora- tion of DNA into a microorganism that, because of natural restrictions in the organism, normally would prevent or limit the incorporation of the DNA. The process involves the selection of an intermediate host organism that has no restric- tions to the incorporation of DNA. The DNA is then transferred into the intermediate host which is readily accomplished because there are no restrictions. The DNA is then isolated from the intermediate host and transferred into the target organism. Using this process the natural restric- tions of the host organism are circumvented and DNA is transferred from a source organism to a target organism that normally would not be possible. In this manner desirable characteristics from the source organism can be imparted into the target organism.

5194587

M A L A R I A - S P E C I F I C D N A S E Q U E N C E S , E X P R E S S I O N

P R O D U C T S T H E R E O F , A N D T H E U S E T H E R E O F

Bernhard Knapp, Erika Hundt, Burkhard En- ders, Han Kupper, Gloucester, assigned to Behringwerke Aktiengesellschaft

The invention relates to malaria-specific DNA sequences, to the expression products thereof, and to the use thereof. A combination of three of the expression proteins whose DNA sequences were isolated by screening a lambda gt l l gene bank with a monospccific antiserum against the

5194592

M O N O C L O N A L A N T I B O D I E S T O N O V E L P O L Y P E P T I D E

D E R I V A T I V E S O F H U M A N G R A N U L O C Y T E C O L O N Y

S T I M U L A T I N G F A C T O R

Hajim Yoshida, Kanagawa, Japan assigned to Kyowa Hakko Kogyo Co Ltd

Novel hG-CSF polypeptide derivatives having an amino acid sequence derived from the amino acid sequence of the haman granulocyte colony stimulating factor polypeptide by substitution of at least one amino acid by a different aminoacid and/or deletion of at least one amino acid, recombinant plasmids containing a DNA frag- ment insert coding for any of these hG-CSF polypeptide derivatives, microorganisms car- rying one of such plasmids, and methods of pro- ducing the hG-CSF polypeptide derivatives using the microorganisms are described.

5 1 ~ 5 ~

C H I M E R I C G L Y C O P R O T E I N S C O N T A I N I N G I M M U N O G E N I C

S E G M E N T S O F T H E G L Y C O P R O T E I N S O F H U M A N

R E S P I R A T O R Y S Y N C Y T I A L V I R U S

Michael W Wathen assigned to The Upjohn Company

This invention encompasses DNA compositions encoding novel chimeric glycoproteins which are useful for preparing virus specific immune responses against haman respiratory syncytial virus. The DNA compositions include structural genes coding for the glycoprot¢ins and expres- sion and replication plasmids containing the structural genes. Host cells transformed with the above DNA compositions, vaccines made from the glycoprotcins and methods for protecting humans by inoculation with said vaccines are also part of this invention.